Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Recruiting

Phase 2

Phase 3

Nivolumab with Usual TreatmentAdding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Sponsor:

National Cancer Institute (NCI)

Code:

NCT06203600

Conditions

Advanced Esophageal Adenocarcinoma

Advanced Gastric Adenocarcinoma

Advanced Gastroesophageal Junction Adenocarcinoma

Clinical Stage II Esophageal Adenocarcinoma AJCC v8

Clinical Stage III Esophageal Adenocarcinoma AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Computed Tomography

Magnetic Resonance Imaging

Nivolumab

Paclitaxel

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-02. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-08-13.